Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Accumulated Expenses data on file, last reported at $275.8 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $275.8 million, up 122.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $275.8 million (up 122.09% YoY), and the FY2025 annual result was $260.4 million, up 108.82% from the prior year.
• Accumulated Expenses climbed to $275.8 million in Q1 2026 per MDGL's latest filing, from $260.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $345.4 million in Q3 2025 and troughed at $53.4 million in Q1 2022.
• A 5-year average of $133.1 million and a median of $92.3 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses slipped 1.62% in 2023, then soared 163.64% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $91.5 million in 2022, then decreased by 1.62% to $90.0 million in 2023, then soared by 38.58% to $124.7 million in 2024, then surged by 108.82% to $260.4 million in 2025, then rose by 5.9% to $275.8 million in 2026.
• Business Quant data shows MDGL's Accumulated Expenses at $275.8 million in Q1 2026, $260.4 million in Q4 2025, and $345.4 million in Q3 2025.